Among the four compounds investigated, M-MeI was found to suppress multiple signaling pathways related to PCa progression, including classical target AR as well as the Akt survival pathway, making it a promising candidate for future therapeutic studies. Here, AKT1 is linked to posterior cortical atrophy.